Petrelintide
Petrelintide (long-acting amylin analogue)
A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.
Overview
Petrelintide is a long-acting amylin analogue developed by Zealand Pharma and Roche as a stand-alone obesity therapy, on the idea that amylin-based drugs may be better tolerated than GLP-1 agonists. The Phase 2 ZUPREME-1 trial reported about 10.7% weight loss at 42 weeks, and it is planned to move to Phase 3 in the second half of 2026. It is investigational.
Mechanism of action
Agonizes amylin receptors to promote satiety and slow gastric emptying, used as a single-agent weight-loss approach.
Key studies & citations
- Animal2025
Development of petrelintide: a potent, stable, long-acting human amylin analogue
Medicinal chemistry paper describing the design of petrelintide as a stable, long-acting human amylin analogue for weekly dosing.
Journal of Medicinal Chemistry - Human2026
Safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management: two randomized, controlled phase 1 trials
Well tolerated with mostly mild GI events and clinically relevant weight loss; supports development for weight management.
Diabetes, Obesity and Metabolism - Human2026
Zealand Pharma announces positive Phase 2 results for petrelintide (ZUPREME-1)
March 5, 2026: 493 participants; up to 10.7% mean weight loss at 42 weeks versus 1.7% with placebo; Phase 3 to start later in 2026.
Zealand Pharma press release
Frequently asked questions
Why develop an amylin-only drug?
Amylin analogues like petrelintide may cause less nausea than GLP-1 drugs, so they are being tested both alone and in combinations for better tolerability.